Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Clinical Outcomes
100%
B-CLL
100%
Molecular Features
44%
Biologic Features
33%
Fludarabine
22%
Immunoglobulin
22%
Cyclophosphamide
22%
Chromosomal Abnormalities
22%
CLL Patients
22%
Gemcitabine
22%
Apoptosis
22%
Leukemia
22%
Somatic mutation
22%
B-cell Clone
11%
Clinical Trials
11%
Apoptosis Resistance
11%
Cellular Feature
11%
Treatment Group
11%
Cancer Treatment
11%
Previously Treated
11%
Disease Therapeutics
11%
Gene Expression Profile
11%
Gene Regions
11%
Predicting Disease
11%
Mutation Type
11%
North Central
11%
Therapeutic Response
11%
Response Rate
11%
Genetic Features
11%
Response Variable
11%
Discriminating Features
11%
Patient Subgroups
11%
Molecular Parameters
11%
Immunoglobulin Heavy Chain Gene
11%
Cytogenetic Abnormalities
11%
Inter-patient Variability
11%
Curative Approach
11%
Specific Hypothesis
11%
Mutation Specific
11%
Therapeutic Strategies
11%
Previously Untreated
11%
Clinical Response
11%
Germline
11%
Disease Subtypes
11%
Drug Sensitivity
11%
Leukemia Patients
11%
Disease Progression
11%
Immunoglobulin Genes
11%
Biological Characteristics
11%
Mutation Status
11%
Immunology and Microbiology
B Cell
100%
Programmed Cell Death
33%
Intravenous Immunoglobulin
22%
Cyclophosphamide
22%
Somatic Mutation
22%
Biological Product
22%
Cell Clone
11%
Immunoglobulin Gene
11%
Drug Sensitivity
11%
Germ Cell
11%
Gene Expression
11%
Immunoglobulin Heavy Chain
11%